Premium
Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis
Author(s) -
Ichinose Yukito,
Yano Tokujiro,
Asoh Hiroshi,
Yokoyama Hideki,
Fukuyama Yasuro,
Miyagi Jun,
Kuninaka Shinji,
Terazaki Yasuhiro
Publication year - 1997
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199711)66:3<196::aid-jso8>3.0.co;2-7
Subject(s) - medicine , thoracotomy , adverse effect , cisplatin , pleural disease , surgery , malignant pleural effusion , chemotherapy , pleural effusion , pleurisy , respiratory disease , anesthesia , lung
Background and Objectives We recently developed a new intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non‐small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods Twenty‐one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results The survival rates in the treatment and non‐treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non‐treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non‐treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events. J. Surg. Oncol. 1997;66:196–200. © 1997 Wiley‐Liss, Inc.